Connect with us

Hi, what are you looking for?

Stock

Moderna shares jumped 15% on Wednesday: this is why

Shares of Moderna Inc (NASDAQ: MRNA) jumped as much as 15% this morning after the biotechnology company built on an agreement it signed with Merck & Co Inc (NYSE: MRK) in 2016.  

Moderna partners with Merck

On Wednesday, the Kenilworth-headquartered multinational exercised an option that enables it to work with Moderna on developing and eventually commercializing mRNA-4157/V940 – a personalised cancer vaccine.

The two companies, as per the press release, will equally share costs so long that the investigational vaccine is in development phase and then profits once it starts to generate sales.

Moderna’s mRNA-4157/V940 is currently being studied with Merck’s Keytruda as an adjuvant treatment for high-risk melanoma. Data from this mid-stage trial is expected in the fourth quarter of 2022.

Merck shares are keeping roughly flat on Wednesday.

Jim Cramer reacts to the news

Moderna, the press release confirmed, will receive $250 million as Merck exercises that option. Reacting to the news on CNBC’s “Squawk on the Street”, Jim Cramer said:

I think this man [CEO Stephane Bancel] is so underestimated. I think this stock is so underestimated. It’s extraordinary. This company is so different because it’s mRNA; because the man behind it is a dreamer executing so well on his dream.

His constructive outlook is in line with Wall Street that also wants you to buy Moderna shares as they have upside to $220 – about a 65% increase from here.

The Nasdaq-listed firm expects its COVID vaccine to generate $21 billion in sales this year. Its next quarterly report is scheduled for early next month.  

The post Moderna shares jumped 15% on Wednesday: this is why appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Stock

    Solana (SOL/USD) is enormously underrated as a cryptocurrency project, even with its hiccups – including the latest exploit on one of the ecosystem apps....

    Editor's Pick

    The new eSIM infrastructure will help modernise the IoT connectivity market with fast, secure connections and reduced vendor lock-in. 1oT, a tech startup from...

    Economy

    The latest Job Openings and Labor Turnover Survey from the Bureau of Labor Statistics shows the total number of job openings in the economy...

    Economy

    U.S. District Court Judge Reed O’Connor recently ruled to uphold the rights of employers granted in the Religious Freedom Restoration Act, rather than uphold...

    Disclaimer: Dealwithbiz.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2023 Dealwithbiz.com